JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 14, 2008; DOI: 10.1124/jpet.108.140749


0022-3565/09/3281-284-293$20.00
JPET 328:284-293, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.140749v1
328/1/284    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang-Park, M.-H.
Right arrow Articles by Moore, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang-Park, M.-H.
Right arrow Articles by Moore, S. D.

NEUROPHARMACOLOGY

µ-Opioid Receptors Selectively Regulate Basal Inhibitory Transmission in the Central Amygdala: Lack of Ethanol Interactions

Maeng-Hee Kang-Park, Brigitte L. Kieffer, Amanda J. Roberts, Marisa Roberto, Samuel G. Madamba, George Robert Siggins, and Scott D. Moore

Department of Psychiatry, Duke University Medical Center, Durham, North Carolina (M.-H.K.-P., S.D.M.); Research Service, Veterans Administration Medical Center, Durham, North Carolina (M.-H.K.-P., S.D.M.); Institut de Génétique et Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/Universitè Louis Pasteur, Strasbourg, France (B.L.K.); and Molecular and Integrative Neuroscience Department, Scripps Research Institute and Alcohol Research Center, La Jolla, California (A.J.R., M.R., S.G.M., G.R.S.)

Endogenous opioid systems are implicated in the actions of ethanol. For example, µ-opioid receptor (MOR) knockout (KO) mice self-administer less alcohol than the genetically intact counterpart wild-type (WT) mice (Roberts et al., 2000). MOR KO mice also exhibit less anxiety-like behavior than WT mice (Filliol et al., 2000). To investigate the neurobiological mechanisms underlying these behaviors, we examined the effect of ethanol in brain slices from MOR KO and WT mice using sharp-electrode and whole-cell patch recording techniques. We focused our study in the central nucleus of the amygdala (CeA) because it is implicated in alcohol drinking behavior and stress behavior. We found that the amplitudes of evoked inhibitory postsynaptic currents (IPSCs) or inhibitory postsynaptic potentials (IPSPs) were significantly greater in MOR KO mice than WT mice. In addition, the baseline frequencies of spontaneous and miniature GABAA receptor-mediated inhibitory postsynaptic currents were significantly greater in CeA neurons from MOR KO than WT mice. However, ethanol enhancements of evoked IPSP and IPSC amplitudes and the frequency of miniature IPSCs were comparable between WT and MOR KO mice. Baseline spontaneous and miniature excitatory postsynaptic currents (EPSCs) and ethanol effects on EPSCs were not significantly different between MOR KO and WT mice. Based on knowledge of CeA circuitry and projections, we hypothesize that the role of MOR- and GABA receptor-mediated mechanisms in CeA underlying reinforcing effects of ethanol operate independently, possibly through pathway-specific responses within CeA.


Received for publication May 12, 2008
Accepted October 10, 2008.

Address correspondence to: Scott D. Moore, 116A, 508 Fulton St., Durham Veterans Administration Medical Center, Building 16, Room 25, Durham, NC 27705. E-mail sdmoore{at}duke.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.